Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)5.70
  • Today's Change0.07 / 1.24%
  • Shares traded13.05m
  • 1 Year change-16.42%
  • Beta0.8382
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform5
Hold4
Sell0
Strong Sell0

Share price forecast in CNY

The 8 analysts offering 12 month price targets for 3SBio Inc have a median target of 7.82, with a high estimate of 10.02 and a low estimate of 6.21. The median estimate represents a 37.18% increase from the last price of 5.70.
High75.9%10.02
Med37.2%7.82
Low8.9%6.21

Dividends

Historical dividend information is not available for 3SBio Inc.
Div growth (TTM)--
More ▼

Earnings history & estimates in CNY

3SBio Inc reported annual 2023 earnings of 0.62 per share on Mar 20, 2024.
Average growth rate+19.46%
More ▼

Revenue history & estimates in CNY

3SBio Inc. had revenues for the full year 2023 of 7.82bn. This was 13.94% above the prior year's results.
Average growth rate+10.18%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.